Understanding the Long-term Paths of People With Addictions (ADDICT AQUI)
Trajectories of People With Substance or Behavioral Addictions in Contact With the Healthcare System: Medical, Neurobiological, Sociological, and Psychological Characteristics. Multicenter, Multidisciplinary Prospective Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Marc AURIACOMBE, Prof, MD, PhD
- Phone Number: +33 5 56 56 17 38
- Email: marc.auriacombe@u-bordeaux.fr
Study Contact Backup
- Name: Helen SAVARIEAU
- Phone Number: + 33 556563556
- Email: hsavarieau@ch-perrens.fr
Study Locations
-
-
Gironde
-
Bordeaux, Gironde, France, 33076
- Recruiting
- Centre Hospitalier Charles Perrens
-
Contact:
- Nicole DUBUCH
- Phone Number: +33556563556
- Email: ndubuch@ch-perrens.fr
-
Contact:
- helen SAVARIEAU
- Phone Number: +33 556563556
- Email: hsavarieau@ch-perrens.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Seeking treatment for substance or behavioral addiction at one of the inclusion centers, with more than one month to wait before treatment begins
- Presenting with at least one substance or behavioral addiction (according to DSM5 criteria)
Exclusion Criteria:
- Condition incompatible with understanding assessment tools
- Difficulties understanding and/or writing French
- Person unable to give personal consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Usual care
|
Once recruited, self-questionnaires completed by the participant at home and brought back at next visite, during which the participant takes cognitive tests.
Follow-up interviews are scheduled at 3 months, 6 months, and then every 6 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severity of addiction
Time Frame: at Day 0, at Month 3, at Month 6 and at each following 6-month visit
|
ASI composite score
|
at Day 0, at Month 3, at Month 6 and at each following 6-month visit
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marc AURIACOMBE, Prof Md PhD, CH. Charles Perrens
Publications and helpful links
General Publications
- Petry NM, Blanco C, Auriacombe M, Borges G, Bucholz K, Crowley TJ, Grant BF, Hasin DS, O'Brien C. An overview of and rationale for changes proposed for pathological gambling in DSM-5. J Gambl Stud. 2014 Jun;30(2):493-502. doi: 10.1007/s10899-013-9370-0.
- Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013 Aug;170(8):834-51. doi: 10.1176/appi.ajp.2013.12060782.
- O'Brien C. Addiction and dependence in DSM-V. Addiction. 2011 May;106(5):866-7. doi: 10.1111/j.1360-0443.2010.03144.x. Epub 2010 Oct 6.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 01-20 ADDICTAQUI
- CCPPRB BORDEAUX B (Other Identifier: Ethic Committee)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.